

# MarÃ-a Teresa Ãlvarez RomÃ;n

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8758729/publications.pdf>

Version: 2024-02-01

48  
papers

410  
citations

840119

11  
h-index

794141

19  
g-index

50  
all docs

50  
docs citations

50  
times ranked

606  
citing authors

#	ARTICLE	IF	CITATIONS
1	Procoagulant State of Sleep Apnea Depends on Systemic Inflammation and Endothelial Damage. <i>Archivos De Bronconeumologia</i> , 2022, 58, 117-124.	0.4	20
2	Clinical assessment and point of care ultrasonography: How to diagnose haemophilic synovitis. <i>Haemophilia</i> , 2022, 28, 138-144.	1.0	11
3	Efficacy and safety evaluation of Fanhdi <sup>®</sup> , a plasma-derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study. <i>Haemophilia</i> , 2022, 28, .	1.0	1
4	Total knee arthroplasty in hemophilia: lessons learned and projections of what's next for hemophilic knee joint health. <i>Expert Review of Hematology</i> , 2022, 15, 65-82.	1.0	5
5	Clinical Efficacy and Safety of Fanhdi <sup>®</sup> , a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210743.	0.7	1
6	Arthropathy in people with mild haemophilia: Exploring risk factors. <i>Thrombosis Research</i> , 2022, 211, 19-26.	0.8	9
7	Acquired Haemophilia A: A 15-Year Single-Centre Experience of Demography, Clinical Features and Outcome. <i>Journal of Clinical Medicine</i> , 2022, 11, 2721.	1.0	3
8	COVID-19 and telemedicine in haemophilia in a patient with severe haemophilia A and orthopaedic surgery. <i>Haemophilia</i> , 2021, 27, e137-e139.	1.0	11
9	Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEAD <sup>®</sup> US system. <i>Haemophilia</i> , 2021, 27, 479-487.	1.0	8
10	Care for children with haemophilia during COVID-19: Data of the PedNet study group. <i>Haemophilia</i> , 2021, 27, e537-e539.	1.0	1
11	Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency. <i>Blood Reviews</i> , 2021, 50, 100833.	2.8	6
12	Applying World Health Organization 2020 guidelines on physical activity and sedentary behavior to people with hemophilia. <i>Expert Review of Hematology</i> , 2021, 14, 429-436.	1.0	7
13	Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1165-1171.	1.4	3
14	Management of acquired hemophilia A: results from the Spanish registry. <i>Blood Advances</i> , 2021, 5, 3821-3829.	2.5	18
15	The factor VIII treatment history of non-severe hemophilia A: COMMENT. Joint damage in adult patients with mild or moderate hemophilia A evaluated with the HEAD <sup>®</sup> US system. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2638-2641.	1.9	7
16	Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A. <i>BMJ Open</i> , 2021, 11, e044997.	0.8	0
17	Evaluation of Platelet Function Defects in Patients with Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 1021-1021.	0.6	0
18	Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients with Severe Hemophilia A: Interim Results of a Post-Marketing, Interventional Study. <i>Blood</i> , 2021, 138, 4915-4915.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Laboratory Characterization of Unclassified Bleeding Disorders By Non-Conventional Tests. <i>Blood</i> , 2021, 138, 4235-4235.	0.6	0
20	Glycomic Characterization of Platelets from Patients with Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 3158-3158.	0.6	1
21	Evaluation of Global Coagulation Tests for Monitoring Bleeding Phenotypes and Response to Treatments in FVII Deficiency. <i>Blood</i> , 2021, 138, 1046-1046.	0.6	0
22	Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1395-1406.	1.8	13
23	What COVID-19 can mean for people with hemophilia beyond the infection risk. <i>Expert Review of Hematology</i> , 2020, 13, 1073-1079.	1.0	7
24	HJHS 2.1 and HEAD-US assessment in the hemophilic joints: How do their findings compare?. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 387-392.	0.5	14
25	Clinical trials and Haemophilia during the COVID-19 pandemic: Madrid's experience. <i>Haemophilia</i> , 2020, 26, e247-e249.	1.0	5
26	Intra-articular injections in people with haemophilia in the COVID-19 era. <i>Haemophilia</i> , 2020, 26, e250-e252.	1.0	4
27	Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2202-2204.	1.9	15
28	Registry of patients with congenital bleeding disorders and COVID-19 in Madrid. <i>Haemophilia</i> , 2020, 26, 773-778.	1.0	18
29	Efficacy and safety of rIX-FP in surgery: An update from a phase 3b extension study. <i>Thrombosis Research</i> , 2020, 193, 139-141.	0.8	3
30	Platelet and immune characteristics of immune thrombocytopaenia patients non-responsive to therapy reveal severe immune dysregulation. <i>British Journal of Haematology</i> , 2020, 189, 943-953.	1.2	27
31	Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain. <i>European Journal of Haematology</i> , 2020, 105, 94-100.	1.1	2
32	Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis. <i>Global &amp; Regional Health Technology Assessment</i> , 2019, 2019, 228424031988053.	0.2	5
33	Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists. <i>Thrombosis and Haemostasis</i> , 2019, 119, 645-659.	1.8	31
34	Joint status in Spanish haemophilia B patients assessed using the Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score. <i>Haemophilia</i> , 2019, 25, 144-153.	1.0	11
35	Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study. <i>Blood</i> , 2019, 134, 4943-4943.	0.6	0
36	The value of HEAD-US system in detecting subclinical abnormalities in joints of patients with hemophilia. <i>Expert Review of Hematology</i> , 2018, 11, 253-261.	1.0	49

#	ARTICLE	IF	CITATIONS
37	Platelet Protein Glycosylation in Immune Thrombocytopenia. <i>Blood</i> , 2018, 132, 2437-2437.	0.6	2
38	99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry. <i>Blood</i> , 2018, 132, 2472-2472.	0.6	0
39	Platelet Dysfunction and Cellular Microparticles May be Involved in the Hipercoagulable State Observed in Obstructive Sleep Apnea Syndrome. <i>Blood</i> , 2018, 132, 5048-5048.	0.6	0
40	Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice. <i>International Journal of Hematology</i> , 2017, 106, 508-516.	0.7	39
41	Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors. <i>European Journal of Haematology</i> , 2016, 96, 461-474.	1.1	15
42	Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. <i>European Journal of Haematology</i> , 2016, 97, 297-302.	1.1	34
43	Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study. <i>Blood</i> , 2016, 128, 3774-3774.	0.6	0
44	Usefulness of Eltrombopag in Secondary ITP Patients in Clinical Practice. <i>Blood</i> , 2015, 126, 2263-2263.	0.6	0
45	Efficacy and Safety of Eltrombopag in Persistent and Newly Diagnosed ITP. <i>Blood</i> , 2015, 126, 4657-4657.	0.6	0
46	Use of Eltrombopag after Romiplostim in Primary ITP Patients. <i>Blood</i> , 2014, 124, 2790-2790.	0.6	0
47	Successful Discontinuation of Eltrombopag after Complete Remission in Patients with Primary Immune Thrombocytopenia. <i>Blood</i> , 2014, 124, 1465-1465.	0.6	0
48	Plasma-derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study. <i>Haemophilia</i> , 0, , .	1.0	2